News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Zimmer Biomet reported an operational reset and modest Q3 beat, making its stock an asymmetric buy relative to free cash flow.
  • Analyst recommends entry near $101, stop below $95 and target around $112.50 for a mid-term Zimmer Biomet trade.
  • Prenetics shares plunged to $8.97 after marketing and financing headlines, creating a tactical long opportunity amid high volatility.
  • Prenetics still shows 200%+ revenue growth, $171M liquidity and zero debt, supporting upside despite headline risk.
  • Federal ICE officers detained two people on a Sea-Tac jetway during boarding, prompting immediate political backlash.
  • Washington officials, the state labor council and Alaska Airlines criticized the arrests, raising operational and reputational risk for carriers.

Latest Articles

Paylocity announces Q4 FY26 earnings conference call

Paylocity announces Q4 FY26 earnings conference call

Paylocity Holding Corporation announced its upcoming conference call to discuss fourth quarter and fiscal 2026 results, scheduled for August 4, 2026. The company provides cloud-based HR, Finance, and IT software solutions, promoting an integrated platform with AI-driven features to enhance workplace operations.

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC Pharmaceuticals announced the initiation of the global Phase 3 Himalayas-1 trial evaluating rinzimetostat in combination with Bayer's darolutamide (NUBEQA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone. The trial will enroll approximately 600 patients across 25 countries to assess …

AVITA Medical to Announce Second Quarter 2026 Financial Results

AVITA Medical to Announce Second Quarter 2026 Financial Results

AVITA Medical, a therapeutic acute wound care company, announced that it will report its second quarter 2026 financial results on August 6, 2026, after U.S. market close. The company will hold a conference call and webcast to discuss results and business highlights. The company specializes in wound healing technologies including RECELL, an FDA-appr…

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Rapid7, Inc., a NASDAQ-listed AI-powered managed cybersecurity operations company, announced it will report its Q2 2026 financial results on August 10, 2026, followed by a conference call to discuss the results and outlook. The company provides cybersecurity services to over 11,500 customers globally, focusing on AI-driven threat detection and risk…

Apollo Funds Complete Acquisitions of Emerald and Questex, Creating a Scaled, B2B Experiential Events and Media Platform Positioned to Drive Sustained, Long-Term Growth

Apollo Funds Complete Acquisitions of Emerald and Questex, Creating a Scaled, B2B Experiential Events and Media Platform Positioned to Drive Sustained, Long-Term Growth

Apollo-managed funds have completed the acquisitions of Emerald Holding, Inc. and Questex, LLC, combining two major B2B event organizers into a scaled, experiential events and media platform. The integration aims to accelerate organic growth, expand capabilities, and enhance value for stakeholders. Leadership appointments have been announced to ste…

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Annexon, Inc. announced an upcoming oral presentation at ASRS 2026 highlighting baseline characteristics linked to vision loss in geographic atrophy patients from the Phase 2 ARCHER trial of vonaprument, its novel neuroprotective therapy. The Phase 2 results demonstrated significant preservation of vision in dry age-related macular degeneration pat…